The second flaw is that "people aren't inherently good reporters," thus reports aren't necessarily complete, leading to more quantity than quality. Gardner provided anticipated developments in postmarket surveillance for the next year: 1. CDRH is looking to collaborate with other agencies in developing effective registries for postapproval studies. 2. A pilot program for electronic medical device reporting should be starting in January. Â